A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Clinical trial NCT06994676 · RECRUITING

Trial details

NCT number: NCT06994676
Sponsor: Crossbow Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

High-risk Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia Chronic Myeloid Leukemia

Start date: 2025-07-16
Primary completion: 2027-01-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.